Company / Cash & Equivalents
ARVINAS, INC. Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$142.9M
FY2025
5-year range
$100.5M / $588.4M
FY2021-FY2025
Trend
+42.2%
vs FY2024
Sector context
#116 of 207
Health Care
What the data says
At $143M, ARVINAS, INC.'s cash & equivalents ranks #116 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 9 years, ranging from $3M in FY2018 to $588M in FY2021.
Based on SEC 10-K filings.
$143M in FY2025 with a 5-year CAGR of -24.7%.
Declined from $312M to $143M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +9.7%
- 5-Year CAGR
- -24.7%
- 10-Year CAGR
- -
Sector benchmark
#116 of 207 in Health CareTop 56% of 207This company $142.9M Sector average $669.5M
▼
-78.7% below sector average
Key checks
Key Insights
- 5-year CAGR of -24.7%, indicating a declining trend.
- In FY2025, cash & equivalents increased 42.2% year-over-year.
- Ranks #116 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -0.85 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $142.9M | +42.2% |
| FY2024 | $100.5M | -67.8% |
| FY2023 | $311.7M | +187.8% |
| FY2022 | $108.3M | -81.6% |
| FY2021 | $588.4M | +0.0% |
| FY2020 | $588.4M | +6288.0% |
| FY2019 | $9.2M | +188.7% |
| FY2018 | $3.2M | -89.7% |
| FY2017 | $30.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026